European Respiratory Journal · 2018 · 43 citations · 36 references
MedicineImmunologyOncologyCutaneous OncologyMetastasisSleep MedicineCutaneous Metastatic DiseaseImmuno-oncology BiomarkersMelanocytic TumorsStaging Of Skin CancerTumor MarkersTumor-associated AntigensBiomarker DetectionClark Level Of InvasionCutaneous Melanoma StagingMelanoma BiomarkersMitotic RateProgrammed Cell Death Protein 1 (Pd-1) PathwayProgrammed Death-ligand 1 BiomarkerTumor Aggressiveness Assessment
Obstructive sleep apnoea (OSA) upregulates the programmed cell death-1 receptor and its ligand (PD-L1) pathway, potentially compromising immunosurveillance. We compared circulating levels of soluble PD-L1 (sPD-L1) in patients with cutaneous melanoma according to the presence and severity of OSA, and evaluated relationships with tumour aggressiveness and invasiveness.In a multicentre observational study, 360 patients with cutaneous melanoma underwent sleep studies, and serum sPD-L1 levels were assayed using ELISA. Cutaneous melanoma aggressiveness indices included mitotic rate, Breslow index, tumour ulceration, Clark level and tumour stage, and sentinel lymph node (SLN) metastasis was recorded as a marker of invasiveness.sPD-L1 levels were higher in severe OSA compared to mild OSA or non-OSA patients. In OSA patients, sPD-L1 levels correlated with Breslow index and were higher in patients with tumour ulceration, advanced primary tumour stages or with locoregional disease. The incorporation of sPD-L1 to the classic risk factors to SLN metastasis led to net improvements in the classification of 27.3%.Thus, sPD-L1 levels are increased in melanoma patients with severe OSA, and, in addition, might serve as a potential biomarker of cutaneous melanoma aggressiveness and invasiveness in this group of subjects.
36
José M. Marı́n, Santiago Carrizo, Eugenio Vicente et al. · The Lancet · 2005 · 4.7K citations